Scott M. Langille
Plus aucun poste en cours
Profil
Scott M.
Langille formerly worked at Biovail Corp., as Director-Corporate Finance, Aralez Pharmaceuticals Canada, Inc., as CFO, Director & Head-Investor Relations from 2011 to 2016, AltiMed Pharmaceuticals Co., as Finance Director, Biovail Pharmaceuticals Canada, as Finance Director, Sparta Capital Ltd., as Chief Financial Officer, Sernova Corp., as Chief Financial Officer from 2016 to 2018, Wayland Group Corp., as Chief Financial Officer, ViRexx Medical Corp., as Chief Financial Officer from 2006 to 2007, Cipher Pharmaceuticals, Inc., as Chief Financial Officer from 2020 to 2022, Biovail Pharmaceuticals LLC, as Vice President, Zimmer of Canada Ltd., as Controller, and Pure Global Cannabis, Inc., as Chief Financial Officer in 2020.
Mr. Langille received his undergraduate degree from Toronto Metropolitan University of and Masters Business Admin degree from the University of Toronto.
Anciens postes connus de Scott M. Langille
| Sociétés | Poste | Fin |
|---|---|---|
| CIPHER PHARMACEUTICALS INC. | Directeur Financier/CFO | 15/08/2022 |
| PURE GLOBAL CANNABIS INC. | Directeur Financier/CFO | 01/05/2020 |
| SERNOVA CORP. | Directeur Financier/CFO | 04/05/2018 |
| TRIBUTE PHARMACEUTICALS CANADA INC | Directeur Financier/CFO | 01/01/2016 |
ViRexx Medical Corp.
 ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Directeur Financier/CFO | 01/05/2007 |
Formation de Scott M. Langille
| Toronto Metropolitan University of | Undergraduate Degree |
| University of Toronto | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| SPARTA CAPITAL LTD. | Utilities |
| SERNOVA CORP. | Health Technology |
| WAYLAND GROUP CORP. | Process Industries |
| CIPHER PHARMACEUTICALS INC. | Health Technology |
| PURE GLOBAL CANNABIS INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Biovail Corp.
 Biovail Corp. Pharmaceuticals: MajorHealth Technology Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Aralez Pharmaceuticals Canada, Inc.
 Aralez Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Aralez Pharmaceuticals Canada, Inc. operates as a pharmaceutical company which focuses on the acquisition, licensing, development, and promotion of healthcare products. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The company was founded by Peter Roy Riehl and Robert Paul Harris on November 14, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
Biovail Pharmaceuticals LLC
 Biovail Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Biovail Pharmaceuticals, Inc. researches and develops pharmaceutical medicines. The company products include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. The company is headquartered in Bridgewater, NJ. | Health Technology |
| AltiMed Pharmaceuticals Co. | |
| Zimmer of Canada Ltd. | |
Biovail Pharmaceuticals Canada
 Biovail Pharmaceuticals Canada Medical DistributorsDistribution Services Biovail Pharmaceuticals Canada sells pharmaceutical products. The private company is based in Mississauga, Canada. | Distribution Services |
